Search Results for "Pregnancy"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Pregnancy. Results 441 to 450 of 968 total matches.
Sotatercept (Winrevair) for Pulmonary Arterial Hypertension
The Medical Letter on Drugs and Therapeutics • May 13, 2024 (Issue 1702)
.
Erythrocytosis, severe thrombocytopenia, and serious
bleeding can occur.
PREGNANCY AND LACTATION — No adequate ...
The FDA has approved sotatercept-csrk (Winrevair –
Merck), a first-in-class activin signaling inhibitor, to
increase exercise capacity, improve WHO functional
class, and reduce the risk of clinical worsening
events in adults with WHO Group 1 pulmonary arterial
hypertension (PAH).
Med Lett Drugs Ther. 2024 May 13;66(1702):73-5 doi:10.58347/tml.2024.1702a | Show Introduction Hide Introduction
Insect Repellents
The Medical Letter on Drugs and Therapeutics • Jul 12, 2021 (Issue 1628)
bites.26,27
PREGNANCY — The CDC considers EPA-registered
formulations of DEET, picaridin, IR3535, OLE ...
The Centers for Disease Control and Prevention
(CDC) and the Environmental Protection Agency
(EPA) recommend using insect repellents to prevent
infections transmitted by mosquitoes and ticks.
Insect repellents applied to exposed skin should be
used in conjunction with other preventive measures
such as wearing pants and long-sleeved shirts and
avoiding outdoor activities during peak mosquito-biting
times. Mosquitoes can transmit diseasecausing
pathogens, including Zika, chikungunya,
dengue, West Nile, eastern equine encephalitis, and
yellow fever viruses, and the malaria parasite....
Drugs for Smoking Cessation
The Medical Letter on Drugs and Therapeutics • Jul 15, 2019 (Issue 1576)
cell dysfunction.49
PREGNANCY — Counseling is the preferred treatment
for pregnant women who smoke ...
Smoking tobacco remains the primary preventable
cause of death in the US. Smoking cessation often requires
both pharmacotherapy and behavioral support.
Podofilox For Genital Warts
The Medical Letter on Drugs and Therapeutics • Dec 13, 1991 (Issue 859)
is not recommended for use
during pregnancy. A 3.5-ml bottle of Condylox with 24 cotton-tipped applicators costs ...
Podofilox 0.5% solution (Condylox - Oclassen) was recently approved by the US Food and Drug Administration for treatment of (condylomata acuminata). The drug requires a prescription, but is labeled for application by the patient. Similar topical solutions previously available for this indication are approved only for application by the physician.
Ophthalmic Levocabastine for Allergic Conjunctivitis
The Medical Letter on Drugs and Therapeutics • Apr 15, 1994 (Issue 920)
pregnancy and breast feeding has not been established. Pituitary adenomas and adenocarcinoma of
the breast ...
A 0.05% ophthalmic solution of levocabastine hydrochloride (Livostin - Iolab), a histamine H 1 -receptor antagonist, has been approved by the US Food and Drug Administration for treatment of seasonal allergic conjunctivitis. The new drug is a cyclohexylpiperidine derivative with no structural relationship to any other antihistamine.
Imiquimod for Genital Warts
The Medical Letter on Drugs and Therapeutics • Dec 19, 1997 (Issue 1016)
of imiquimod in pregnancy is not known.
DOSAGE AND COST — Patients are instructed to apply 5% imiquimod cream ...
Imiquimod (i mi kwi' mod) 5% cream (Aldara - 3M Pharmaceuticals) has been approved by the FDA for treatment of external genital and perianal warts (condyloma acuminata). The drug requires a prescription but is applied by the patient. It is the second patient-applied treatment to become available for external genital warts; the first was podofilox (Condylox - Medical Letter, 33:117, 1991).
Irbesartan for Hypertension
The Medical Letter on Drugs and Therapeutics • Jan 30, 1998 (Issue 1019)
and should not be used during pregnancy.
CONCLUSION — Irbesartan appears to be similar to other angiotensin ...
Irbesartan (Avapro - Sanofi/Bristol-Myers Squibb) is the third angiotensin II receptor antagonist to become available in the USA for oral treatment of hypertension. Losartan (Cozaar) and valsartan (Diovan) were marketed earlier. Eprosartan (Teveten - SmithKline Beecham) has been approved by the FDA but not marketed.
In Brief: Measles Outbreak
The Medical Letter on Drugs and Therapeutics • Jun 02, 2008 (Issue 1287)
to be fully
immunized.
1
Contraindications to the attenuated livevirus vaccine include pregnancy ...
The US Centers for Disease Control and Prevention (CDC) has reported that measles outbreaks have occurred in New York City, California and Arizona in 2008, and additional cases have been confirmed in Michigan, Wisconsin, Hawaii, New York State, Pennsylvania, Illinois and Virginia (CDC Health Advisory, May 1, 2008). To date, 63 of the 64 infected patients were unvaccinated, and 54 of the cases were associated with importation of the disease. Both measles infection and vaccination (2 doses at least 28 days apart, with the first dose no earlier than 12 months of age) generally provide lifelong...
Tribenzor for Hypertension
The Medical Letter on Drugs and Therapeutics • Sep 06, 2010 (Issue 1346)
is contraindicated
for use during pregnancy because of the
ARB component, which can cause fetal toxicity and
death ...
Many patients with hypertension require more than one drug to control their blood pressure. Tribenzor (Daiichi Sankyo), recently approved by the FDA for treatment of hypertension, combines the calcium channel blocker amlodipine (Norvasc, and others), the angiotensin receptor blocker (ARB) olmesartan (Benicar)and the most commonly prescribed diuretic, hydrochlorothiazide (HCTZ). Tribenzor is not approved for initial therapy, but is recommended for patients not adequately controlled on any 2-drug combination of a calcium channel blocker, an ARB or a diuretic.
Dalfampridine (Ampyra) for MS
The Medical Letter on Drugs and Therapeutics • Sep 20, 2010 (Issue 1347)
disorder. The drug is classified as category C (risk
cannot be ruled out) for use in pregnancy.
Dose ...
The FDA has approved the use of dalfampridine (4-aminopyridine; Ampyra – Acorda), a potassium
channel blocker, to improve walking speed in patients with multiple sclerosis (MS). Walking speed is considered
a reliable clinical measure of impairment in patients with MS.